Baird downgraded Ambrx Biopharma (AMAM) to Neutral from Outperform with a $28 price target after Johnson & Johnson (JNJ) announced last week that it has reached agreement to acquire Ambrx for $28 per share. The firm thinks the deal is likely to close, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMAM:
- Ambrx Biopharma downgraded to Market Perform from Outperform at JMP Securities
- Ambrx Biopharma downgraded to Neutral from Buy at B. Riley
- Ambrx Biopharma downgraded to Neutral from Buy at BTIG
- M & A News: Johnson & Johnson (NYSE:JNJ) to Acquire Ambrx Biopharma
- Ambrx Biopharma downgraded to Sector Perform from Outperform at RBC Capital